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ABSTRACT
Objectives: To determine the frequency of lipid testing and to
identify the factors predictive of lipid-testing frequency over
a 1-year period in patients beginning statin treatment.
Methods: Retrospective cohort study performed using the
UK General Practice Research Database. The patients were
selected if they were 35 years of age, received ﬁrst-ever
statin between January 2000 and December 2004, had at
least one total cholesterol (TC), high-density lipoprotein cho-
lesterol (HDL-C), or triglyceride (TG) test conducted in the
1-year period before statin initiation, and had at least 1 year
of follow-up data. The main outcome measures were TC,
HDL-C, and TG testing frequencies in the year after initiating
statins. Poisson regression was used to assess baseline factors
associated with testing frequency for each lipid.
Results: In the year after initiating statins, the patients
received a mean (SD) of 1.3 (1.0) TC tests, 0.9 (1.0)
HDL-C tests, and 0.9 (1.0) TG tests; however, 22.7%,
44.3%, and 39.1% of the patients did not receive any TC,
HDL-C, and TG tests, respectively. In multivariate analyses,
a high coronary heart disease (CHD) risk (odds ratio [OR]
1.04; 95% conﬁdence interval [CI] 1.01–1.07) and elevated
baseline TC (6.2 vs. <5.0 mmol/L; OR 1.12; 95% CI 1.06–
1.18) were signiﬁcantly associated with greater TC testing
frequency.
Conclusions: High risk of CHD and elevated baseline TC
were associated with greater rates of TC testing in the year
after statin initiation. Lack of TC testing in approximately
one in ﬁve patients, and infrequent HDL-C and TG testing
may be barriers to comprehensive lipid management.
Keywords: cholesterol/ lipoproteins, coronary heart disease
risk, HDL-cholesterol/ lipoproteins, triglycerides.
Introduction
Monitoring lipid levels in the year after beginning
lipid-modifying drug therapy is important to deter-
mine whether treatment goals are being met. The UK
guidelines for the prevention of cardiovascular disease
set minimum benchmark targets for low-density lipo-
protein cholesterol (LDL-C), which is the primary
target of statins (the usual initial cholesterol-lowering
drug), and for total cholesterol (TC) [1–3]. Treatment
recommendations, however, are based on the 10-year
risk of coronary heart disease (CHD), which is calcu-
lated from the ratio of TC and high-density lipoprotein
cholesterol (HDL-C) [1,3]. These guidelines also rec-
ognize that elevated triglyceride (TG) levels increase
the risk of CHD. Consequently, decisions on whether
to modify treatment in the year after initiation of drug
therapy should be informed by measurements of TC,
HDL-C, and TG. There is, however, relatively little
information about the type and frequency of lipid
testing after the initiation of lipid drug treatment in the
United Kingdom. The objectives of this study were to
examine the frequency of lipid testing and to identify
variables predictive of the frequency of lipid testing in
the year after patients began their ﬁrst-ever statin treat-
ment in the United Kingdom.
Methods
Study Design
This was a retrospective cohort study of data from the
UK General Practice Research Database (GPRD). The
GPRD database contains computerized information
collected since 1987 by general practitioners (GPs) in
the United Kingdom. Structured data on about
3 million patients are recorded and sent anonymously
to the Medicines and Healthcare Products Regulatory
Agency. This information includes demographics,
details of GP visits, diagnoses from specialists’ referrals
and hospital admissions, results of laboratory tests,
and prescriptions, which are generated directly from
the computers in the GPs’ ofﬁces. The GPRD database
is used extensively and has been validated for use in
health services research [4].
Patient Sample
Patients who received their ﬁrst-ever statin prescrip-
tion on a date (the index date) between January 2000
and December 2004 were identiﬁed. Patients with a
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continuous database history for at least 2 years before
and 1 year after the index date, and who did not
receive a prescription for any lipid-lowering therapy
before the index date, were followed until the earlier of
either 1 year after the index date or the date of statin
discontinuation plus 30 days. A requirement of a
2-year period without statin use before the index date
ensured that the selected patients were an appropriate
proxy to “true” ﬁrst-ever statin users. One-year
periods before (baseline) and after (follow-up) the
index date were used for assessing the lipid values and
measuring the frequency of lipid testing (Fig. 1).
The patients were required to be at least 35 years of
age and to have at least one baseline TC, HDL-C,
or TG test conducted during the baseline period. A
separate LDL-C test was not required as LDL-C
can be computed using the Friedwald formula [5].
The patients were also required to be enrolled in a
pathology-linked practice, deﬁned as any practice from
which laboratory information is automatically coded
and entered into the GPRD database. A practice was
considered to be pathology-linked for a given year if it
satisﬁed the following criteria: at least 45 recorded
potassium laboratory tests; at least 40% of potassium
laboratory test counts with minimum and maximum
value ﬁelds populated; and at least 14 potassium labo-
ratory test counts per quarter. Practices not fulﬁlling
these criteria for more than two consecutive quarters
during the study period were disqualiﬁed. The main
rationale for using potassium lab data was the narrow
range associated with potassium values and indication
of computerized lab linkage through presence of a value
in theminimumandmaximumﬁelds, which have a high
likelihood of being missing if the potassium values are
entered manually. Patients switching from a statin to a
nonstatin lipid-modifying drug therapy during the
follow-up period were excluded from the study.
Study Variables
The main study outcome measures were the numbers
of TC, HDL-C, and TG tests in the year after begin-
ning statin treatment. Sociodemographic variables
included sex, age, and UK region. Clinical variables
included smoking status, body mass index (BMI),
comorbidities (presence of hypertension, diabetes,
ischemic heart disease, and peripheral arterial disease),
and lipid parameters (TC, HDL-C, and TG values). A
high risk of CHD was deﬁned as having a history of
CHD, diabetes, or a projected 10-year CHD risk of
>30%, based on the Framingham primary CHD risk
equation [6]. (Diabetes is considered a CHD-risk
equivalent, and 30% is the highest risk threshold in the
British guidelines in effect during the study period [1]).
Statistical Analysis
The descriptive analyses of patient characteristics and
frequencies of lipid tests were carried out. Baseline
factors predictive of lipid-testing frequency in the
follow-up period were examined using multivariate
Poisson regression. Separate multivariate Poisson
regression analyses were carried out with TC, HDL-C,
and TG test numbers as response variables. The inde-
pendent variables were sex (male vs. female), age
category (55–64, 65–74, and 75 vs. <55 years), UK
region (East, South, mid-, and North England, north-
ern Ireland, and Scotland vs. Wales), index year (2001,
2002, 2003, 2004 vs. 2000), smoking status (yes/no),
BMI category (24–25, 26–27, 28–29, 30 vs. <24),
hypertension (yes/no), CHD risk (high vs. not high),
and, in the TC, HDL-C, and TG models, respectively,
elevated baseline TC (5.0 to <6.2 and 6.2 vs.
<5.0 mmol/L), low baseline HDL-C (<1.0 vs.
1.0 mmol/L for males and <1.2 vs. 1.2 mmol/L for
females), and elevated baseline TG (1.7 to 2.1,
2.2 to 5.5, and 5.6 mmol/L vs. <1.7 mmol/L).
Results
The study population consisted of 57,296 patients,
with a mean age of 65.4 years and a slight preponder-
ance (52.3%) of men (Table 1). The patients received a
mean of 1.3 TC tests, and 0.9 HDL-C and TG tests in
the year after beginning statin treatment (Table 2).
Nevertheless, 22.7% of the patients did not receive a
TC test in the follow-up period, and 44.3% and
39.1%, respectively, of the patients did not receive an
HDL-C or TG test (Fig. 2).
In multivariate analyses, a high risk of CHD and
elevated baseline TC were predictive of TC testing, and
elevated baseline TG (2.2 to <5.6 mmol/L) was
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Figure 1 Schematic of study periods.
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predictive of TG testing (Table 3). Age (75 years),
region (East England vs. Wales), hypertension, and
smoking status were signiﬁcantly associated with 3%
to 10% lower frequencies of TC, HDL-C, and TG
testing, and male sex was associated with 3% lower
frequencies of HDL-C and TG testing (Table 3).
Discussion
Summary of This Study
This was an observational study of lipid-testing rates
among patients who had begun statin therapy in the
United Kingdom in the period 2000 to 2004. In the
year after beginning statin treatment, approximately
one-ﬁfth (22.7%) of patients had no TC test, and
approximately two-ﬁfths had no HDL-C (44%) or TG
(39%) test. Please note that the above percentages are
computed for the whole cohort of 57,296 patients, as
each patient was considered eligible for receiving full
lipid panel after the initiation of statin therapy. Con-
sistent with the UK guidelines, patients with a high risk
of CHD and elevated baseline TC (6.2 mmol/L vs.
TC <5.0 mmol/L) had a 4% and 12% increase in the
likelihood of receiving a TC test after statin therapy
initiation, respectively. Patients with moderately
elevated baseline TG (2.2 to <5.6 mmol/L vs.
<1.7 mmol/L) had a relatively modest 4% increase in
the likelihood of receiving a TG test. Physicians were
slightly (3–6%) less likely to provide a TC test for
patients with certain CHD risk factors, including
advanced age (75 years), smoking, and hypertension.
There was also a regional effect in lipid testing, with
patients in East England 9% to 10% less likely than
those in Wales to receive a TC, HDL-C, and TG test.
This apparent regional disparity in practice patterns
warrants further investigation.
Interpretation of Results
Despite an emphasis on TC management in the UK
guidelines [3], nearly one in ﬁve patients did not receive
a TC test in the year after statin therapy initiation.
There was, however, no difference in the likelihood of
receiving a TC test between patients with moderately
high baseline TC (5.0 to <6.1 mmol/L) and patients
with TC <5.0 mmol/L. This may have occurred because
physicians preferred to perform frequent TC testing
only in patients who were less likely to attain TC goal.
Given the low rates of TC goal attainment—a 1998
survey of England found that only 35% of men
and 20% of women being treated with lipid-lowering
drugs reached the recommended TC concentration of
<5 mmol/L [7], and in the present study, 35% of GPRD
patients failed to achieve the recommended TC goal
[8]—it may be necessary to test patients with moder-
ately elevated as well as very high baseline TC con-
centration. Patients with CHD risk factors—those
75 years, hypertensives, and smokers—appeared less
likely to receive a TC, HDL-C, or TG test during the
follow-up period. These characteristics are easy to iden-
tify in clinical practice and physicians may have initi-
ated and continued therapy on the basis of observation
of these factors, without frequent blood testing. Lower
rates of HDL-C and TG versus TC testing indicate that
TC rather than LDL-C tended to be the primary focus
of physicians. The low frequency of HDL-C and TG
testingmay be a consequence of the exclusion of explicit
HDL-C and TG management recommendations from
the UK guidelines.
Table 1 Sociodemographic and clinical characteristics
Characteristic Percent patients (N = 57,296)
Male sex 52.3
Age category
<55 years 18.3
55–64 years 28.1
65–74 years 33.6
75+ years 20.0
Region
East England 8.9
South England 41.7
Mid-England 19.3
North England 24.9
Other 5.2
Smoking status*
Current smoker 19.0
Ex-smoker 29.9
Never 47.3
BMI*
<24 17.5
24 to <26 15.7
26 to <28 16.6
28 to <30 13.6
30 27.5
Concomitant conditions
Hypertension 52.8
Diabetes 29.2
IHD 27.3
Peripheral arterial disease 5.0
High-risk CHD 61.2
Number of patients with at least one
test at baseline
TC 57,176
HDL-C 41,608
TG 44,043
TC or HDL-C or TG 57,296
Lipid parameters (mmol/L)
TC 6.4 1.2
LDL-C 4.1 1.0
HDL-C 1.4 0.4
TG 2.2 1.5
*Data were missing for 3.8% of smoking status and 9.1% of body mass index (BMI)
ﬁelds.
CHD, coronary heart disease, HDL-C, high-density lipoprotein cholesterol; IHD,
ischemic heart disease;TC, total cholesterol;TG, triglyceride.
Table 2 Number of lipid tests conducted in the year after
statin initiation
Test Mean SD Median
TC 1.3 1.0 1.0
HDL-C 0.9 1.0 1.0
TG 0.9 1.0 1.0
HDL-C, high-density lipoprotein cholesterol;TC, total cholesterol;TG, triglyceride.
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Low Rates of Lipid Testing Have Been Seen in
Published Studies
There have been few other studies examining rates of
lipid testing in the United Kingdom. In two UK studies
of inpatients with CHD in the early 1990s [9], a TC
measurement was recorded for 83% of patients in one
case [10], and for 64% of men and 59% of women in
the other [11]. More recently, in 1997, Holt et al.
prospectively measured the rates of lipid testing in 359
patients discharged after hospitalization for acute myo-
cardial infarction (MI) or revascularization, which indi-
cated that approximately 42% of the patients did not
receive lipid testing within 3 months of discharge [12].
France et al. analyzed the rates of routine lipid testing in
3,573 patients attending 14 general practices in 1999 to
2001 [13]. In that study, rates of lipid testing in non-
South Asian men and women were 11.2% and 13.2%,
respectively—lower than rates in South Asian men and
women (12.1% and 18.6%) [13].
Rates of Lipid TestingWere Not in Accordance with the
UK Guidelines
The observed rates of lipid testing are not in accor-
dance with the UK guidelines in force during the study
period. These guidelines did not specify a lipid-testing
schedule after beginning lipid-lowering drug therapy
[1,3], but it was implicit that lipid testing must be done
to determine whether the speciﬁed TC and LDL-C
goals have been met. The JBS 2 guidelines issued in
2005 at the end of the study period state that high-risk
patients (those with CHD, diabetes, or a 10-year risk
of CHD risk of 15%) have their lipids (TC and
HDL-C) monitored regularly, and not less than once
per year [2]. Lack of TC testing in approximately 22%
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Figure 2 Frequency of lipid testing in the year
after statin initiation. HDL-C, high-density lipo-
protein cholesterol; TC, total cholesterol; TG,
triglyceride.
Table 3 Signiﬁcant predictors of TC, HDL-C, and TG testing frequencies
Variable*
TC
Risk ratio (95% CI)
HDL-C
Risk ratio (95% CI)
TG
Risk ratio (95% CI)
Baseline TC 6.2 mmol/L 1.12 (1.06–1.18) — —
Baseline TG 2.2 to <5.6 mmol/L — — 1.04 (1.01–1.07)
High-risk CHD 1.04 (1.01–1.07) NS NS
Male sex NS 0.97 (0.94–0.99) 0.97 (0.94–0.99)
Age 75 0.94 (0.90–0.99) 0.94 (0.90–0.99) 0.95 (0.90–0.99)
Region (East England) 0.91 (0.85–0.97) 0.90 (0.84–0.97) 0.90 (0.84–0.97)
Smoking 0.96 (0.92–0.99) 0.96 (0.93–0.99) 0.96 (0.92–0.99)
Hypertension 0.97 (0.94–0.99) 0.97 (0.94–0.99) 0.96 (0.94–0.99)
*Reference categories:TC (<5.0 mmol/L);TG < 1.7 mmol/L; nonhigh risk CHD; female sex; age category <55 years; region Wales; nonsmoking status; no hypertension.
Under each model nonsigniﬁcant variables were not included in the results table.
For TC: other nonsigniﬁcant variables were age categories (55–64, 65–74 years), sex (males, females), body mass index (BMI) categories (<24, 24–25, 26–27, 28–29, 30+), index
years (2000, 2001, 2002, 2003, 2004), regions (South England, Mid-England, North England, Northern Ireland, Scotland), and baseline TC (5.0 to 6.1 mmol/L).
For HDL-C: nonsigniﬁcant variables were age categories (55–64, 65–74 years), BMI categories (<24, 24–25, 26–27, 28–29, 30+), sex (males, females), index years (2000, 2001, 2002,
2003, 2004), regions (South England, Mid-England, North England, Northern Ireland, Scotland), and baseline HDL-C (<1.0 mmol/L for males and <1.2 mmol/L for females,
1.0 mmol/L for males and 1.2 mmol/L for females).
ForTG: other nonsigniﬁcant variables are as follows: age categories (55–64, 65–74 years), BMI (<24, 24–25, 26–27, 28–29, 30+), index years (2000, 2001, 2002, 2003, 2004), regions
(South England, Mid-England, North England, Northern Ireland, Scotland), and baseline TG (1.7 to 2.1,5.6+ mmol/L).
—, indicates that the variable was not included in the multivariate model; CHD, coronary heart disease; CI, conﬁdence interval; HDL-C, high-density lipoprotein cholesterol; NS,
not signiﬁcant;TC, total cholesterol;TG, triglyceride.
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patients eligible for this study clearly indicated that
emphasizing the use of clinical guidelines may be one
of the ways to improve lipid management. Rates
of HDL-C and TG testing were worse: nearly 40%
patients did not get tested even once in the year after
statin initiation.
The General Medical Services (GMS) Contract Provides
Little Incentive for Practices to Carry Out Lipid Testing
The new GMS contract, negotiated by the National
Health Service (NHS) Confederation and General
Practitioners Committee of the British Medical Asso-
ciation, and implemented in April 2004 [14], provides
practices with little incentive to carry out lipid testing
of patients after beginning lipid-lowering drugs. The
new system categorizes work into essential services,
which must be provided, and additional and enhanced
services, which practices can chose whether or not to
provide. Payments made to practices are based on a
points system. One thousand points are assigned for
overall achievement of quality indicators, of which
121 points are allocated to the treatment of CHD. The
management of dyslipidemia in the secondary preven-
tion of CHD is an essential service. Patients with CHD
should have a cholesterol test within 3 months and
delivery of clinical standards within 9 months. The
system allocates 7 points for the percentage of patients
with CHD whose notes have a record of TC in the
previous 15 months. For stroke and diabetes, the cor-
responding points are 2 and 3. There are no points for
lipids other than TC and no points for lipid testing in
the primary prevention of CHD. In addition, practices
can exclude newly diagnosed or previously diagnosed
but newly registered patients from the performance
calculation. This exception was retained in the 2006 to
2007 revision [15].
More broadly, the GMS contract does not embrace
the concept of high total cardiovascular risk as empha-
sized in guidelines, and the standards for controlling the
risk factors represent the minimum standard of preven-
tive cardiovascular care in relation to the scientiﬁc
evidence [2]. The scientiﬁc evidence that constitutes the
rationale for lipid testing is embodied in the recommen-
dations of international guidelines for the prevention of
cardiovascular disease. The UK guidelines base their
treatment recommendations on the 10-year risk of
CHD, calculated from the TC/HDL-C ratio [1,3]. The
European guideline recommendations are based on
the 10-year risk of coronary death, calculated from the
plasma level of TC [16,17]. Both sets of guidelines set
minimum benchmark targets for TC and LDL-C of
<5 mmol/L and <3 mmol/L, respectively, and both rec-
ognize that lowHDL-C act as an independent CHD risk
factor. These guidelines also recognize that elevated TG
levels increase the risk of CHD. No speciﬁc targets are
set for TG or HDL-C, but TG and HDL-C levels serve
as indicators for the choice of drug treatment [2,16,17].
In addition, LDL-C, the primary target of statins, is
frequently calculated using the Friedewald formula, in
which LDL-C is a function of TC, HDL-C, and TG
levels [5]. Consequently, the measurement of HDL-C
and TG, as well as TC and LDL-C, is important in
determining the overall risk of CHD and in controlling
lipid risk factors.
Limitations
This study focused on lipid testing after the patients
had begun statin treatment. The design did not allow
rates of lipid testing to be determined in a representa-
tive sample of the population before beginning lipid-
lowering drug therapy, because having at least one
lipid test at baseline was a study inclusion criterion.
This study also did not capture lipid testing in patients
who either switched to a practice not participating in
GPRD or if lipid testing was conducted in a nonpa-
thology linked laboratory setting. As a retrospective
study, it is vulnerable to the limitations associated with
such studies. For instance, we can only speculate about
the inverse relationship between the frequency of TC,
HDL-C, and TG testing and the demographic and
clinical factors known to be associated with increased
risk of CHD. A supporting observational study of
physicians’ preferences in prescribing lipid tests might
reveal the reasons underlying the lower rates of TC,
HDL-C, and TG testing in patients with one or more
CHD risk factors.
Conclusions
Despite the emphasis on TC management in the UK
guidelines, one in ﬁve patients did not receive a
follow-up TC test to assess the effectiveness of statin
treatment. Physicians appeared to test more frequently
patients at high risk of CHD, as computed using the
Framingham primary CHD risk equation, or with very
high TC levels. HDL-C or TG testing frequencies were
inadequate, with nearly two in ﬁve patients failing to
receive a follow-up HDL-C or TG test. Lack of testing
for HDL-C and TG represents a signiﬁcant gap in a
comprehensive lipid management program, given the
fact that accurate assessment of LDL-C was dependent
on testing of HDL-C and TG, and given that HDL-C is
considered a major CHD risk factor and TG is consid-
ered an emerging CHD risk factor.
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